These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger

Biotech company Gilead Sciences (GILD) should buy Celgene's (CELG) psoriasis drug Otezla, but only for less than $9.6 billion, analysts said Thursday.

Earlier this year, Bristol-Myers Squibb (BMY) announced Celgene would divest the blockbuster drug in order to complete Bristol-Myers' $74 billion merger with Celgene. Bristol-Myers already owns psoriatic arthritis drug Orencia. So, owning both drugs could create a monopoly.